Femasys reports Q2 EPS (16c) vs. (21c) last year

Reports Q2 revenue $409,268 vs. $221,484 last year. “Our second quarter marked several significant milestones for Femasys (FEMY) as we continue to secure key regulatory approvals, add partners, and strengthen our team to accelerate the commercialization of our innovative fertility portfolio across the globe,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. “European approval of the entire FemBloc System announced in June marks the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solution. FemBloc is commercially available through strategic distribution partnerships in select countries in Europe beginning in Spain, who placed their initial order, and we will seek additional country approvals while continuing to enroll participants in our FDA IDE-approved late-stage pivotal trial for U.S. approval.” Cash and cash equivalents as of June 30, 2025, was approximately $3.2M and the company had an accumulated deficit of approximately $137.7M. The company expects, based on its current operating plan, our current cash and cash equivalents will be sufficient to fund its ongoing operations into early fourth quarter of 2025.